Skip to main content

Table 10 Selected studies for CLL therapy from 2020 ASH annual meeting

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Abstract # First author (reference) Study agents Phase NCT Study name
127 Al-Sawaf [111] Venetoclax, obinutuzumab III NCT02242942 CLL14
1310 Al-Sawaf [112] Venetoclax, obinutuzumab III NCT02242942 CLL14
123 Wierda [113] Ibrutinib, venetoclax II NCT02910583 CAPTIVATE
3138 Jain [115] Ibrutinib, venetoclax II NCT02756897  
2216 Davids [114] Acalabrutinib, venetoclax, obinutuzumab II NCT03580928  
1307 Soumerai [116] Zanubrutinib, venetoclax, obinutuzumab II NCT03824483 BoVen
125 Kater [117] Venetoclax, rituximab III NCT02005471 MURANO
124 Hillmen [120] Ibrutinib, venetoclax II ISCRTN13751862 CLARITY
543 Gribben [119] Umbralisib, ublituximab III NCT02612311 UNITY-CLL
542 Mato [121] Loxo-305 I/II NCT03740529 BRUIN
545 Benjamini [122] CD19-CART I NCT02772198  
126 Mato [123] DTRM-555 I NCT02900716  
544 Wierda [124] Liso-cel, ibrutinib I NCT03331198 TRANSCEND-004
546 Siddiqi [125] Liso-cel I NCT03331198 TRANSCEND-004